Navigation Links
Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.)
Date:6/22/2010

LAKE FOREST, Ill., June 22 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced it has received U.S. Food and Drug Administration (FDA) approval for meropenem for injection, USP (I.V.) 500 mg and 1 g vials.  The medication, a carbapenem that belongs to the beta-lactam class of antibiotics, is a generic version of AstraZeneca's Merrem® I.V. Sales of the name-brand product in the United States were approximately $200 million in 2009.

"This is the first generic carbapenem approved in the United States, and will help propel Hospira to a position of leadership in this category of antibiotics," said Thomas Moore, president, Hospira, U.S. Region. "Hospira is committed to continuing to reduce the cost of healthcare spending by providing savings with first-to-market generic launches."

Meropenem represents the first U.S. drug launch from Hospira's recent acquisition of the generic injectables business of Orchid Chemicals & Pharmaceuticals, Ltd. Beta-lactam antibiotics represent a class of drugs with a wide spectrum of antibacterial activity. The U.S. market value of beta-lactam molecules is more than $1 billion, based on 2009 sales, according to IMS Health.

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated presentations, several of which are proprietary, such as ADD-Vantage™ drug delivery system and iSecure™ prefilled syringes. Therapeutic segments include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biogeneric drugs.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 13,500 employees. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 -- A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the growth opportunities for generic specialty injectable products. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, legal, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and subsequent Forms 10-Q filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
2. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
3. Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
4. Hospira to Present at Citi 2010 Global Health Care Conference May 27, 2010
5. Hospira Supports Disaster Relief Efforts in Haiti With Products and Cash Grants
6. Hospira to Present at J.P. Morgan 28th Annual Healthcare Conference Jan. 13, 2010
7. Hospira to Host Conference Call for Fourth-Quarter 2009 Results and 2010 Projections
8. Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers
9. Hospira Acquires TheraDoc, Enhances Medication Safety and Infection Management Offerings
10. Hospira Reports Third-Quarter 2009 Results
11. Hospira Names Daphne E. Jones Chief Information Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Physician General Dr. Rachel Levine ... Jennifer Smith commended South Central EMS today for ... naloxone, a life-saving overdose reversal drug. The recognition event ... and overdose survivor who was saved due to the ... significant part of fighting the opioid epidemic is making ...
(Date:2/24/2017)... HILL, N.C. , Feb. 24, 2017 /PRNewswire/ ... are exploring ways to increase their self-service capabilities ... Health Care Providers (HCPs). New research ... many pharma organizations have developed self-service website portals ... electronically.  This is just one of many findings ...
(Date:2/24/2017)... , Feb. 23, 2017 The ... of the PhenoTest BC Kit, performed on the ... identify organisms that cause bloodstream infections and provide ... to respond to (antibiotic sensitivity). The test also ... provide this important information, which can guide antibiotic ...
Breaking Medicine Technology:
(Date:2/24/2017)... , ... February 24, 2017 , ... ... of Liberty University, has officially announced the appointment of Peter A. Bell, DO, ... of Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An ... true account of his paramedic experiences. Schanssema describes the tragedies he saw, as well ... to overcome them. , Schanssema, initially unsure of the career path he wanted to ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) ... company later this year. Dyer started as the Chairman of the Management Committee ... establishment of the corporation including the recruitment of investor/owners and development of the business ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
Breaking Medicine News(10 mins):